Magnesium valproate/Hydralazine hydrochloride

丙戊酸镁/盐酸肼屈嗪

Report date: 2025/07/29 20:00:11

Base Information

Drug NameMagnesium valproate/Hydralazine hydrochloride
Drug Alias NameHydralazine+Magnesium valproate丙戊酸镁+肼屈嗪Magnesium valproate+Hydralazine丙戊酸镁/肼屈嗪肼屈嗪+丙戊酸镁 +[7] 
ClassificationSmall molecules
Mechanisms of ActionGlycogen synthase kinase-3 inhibitorsGamma-amino-N-butyrate transaminase inhibitorsAmine oxidase, copper containing inhibitors
TargetsAmine oxidase, copper containingGamma-amino-N-butyrate transaminaseGlycogen synthase kinase-3
Therapy Area/IndicationsUterine Cervical Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMexico
CombinationsYes Hydralazine hydrochlorideMagnesium valproate
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNeolpharma IncPsicofarma S.A De Cv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPsicofarma S.A De CvNational Institute Of Cancerologia
Active IndicationsN/A
Inactive IndicationsUterine Cervical Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A